Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Br J Ophthalmol. 2022 Nov;106(11):1538-1541. doi: 10.1136/bjophthalmol-2020-318577. Epub 2021 Apr 30.
BACKGROUND/AIMS: To investigate the incidence, severity of COVID-19 infection and the outcomes in patients with uveitis treated with biologic agents during COVID-19 pandemic.
In this prospective study, we included all patients with uveitis treated with biologic agents and tested for COVID-19 infection between May 2020 and October 2020.
A total of 59 patients were identified. Behçet's disease was the most common diagnosis (64.4%). Infliximab was the most frequent biologic agent used (61%). Nine (15.3%) patients were tested positive for COVID-19. None of the patients with positive COVID-19 test developed any COVID-19-related symptoms during follow-up. Of the nine patients with positive COVID-19 test, only two patients had uveitis flare-up after the biologic suspension.
Uveitis patients under biologic therapy can be silent carriers for COVID-19.
背景/目的：研究在 COVID-19 大流行期间使用生物制剂治疗葡萄膜炎的患者 COVID-19 感染的发生率、严重程度和结局。
在这项前瞻性研究中，我们纳入了 2020 年 5 月至 2020 年 10 月期间接受 COVID-19 检测且使用生物制剂治疗葡萄膜炎的所有患者。
共确定了 59 名患者。最常见的诊断是贝切特病（64.4%）。使用最频繁的生物制剂是英夫利昔单抗（61%）。9 名（15.3%）患者的 COVID-19 检测呈阳性。在随访期间，COVID-19 检测呈阳性的患者均未出现任何 COVID-19 相关症状。在 COVID-19 检测呈阳性的 9 名患者中，仅 2 名患者在停用生物制剂后出现葡萄膜炎发作。
接受生物制剂治疗的葡萄膜炎患者可能是 COVID-19 的无症状携带者。
